Ostrowski Ireneusz, Śledź Emil, Ciechan Janusz, Golabek Tomasz, Bukowczan Jakub, Przydacz Mikolaj, Wiatr Tomasz, Stangel-Wojcikiewicz Klaudia, Chłosta Piotr L
Department of Urology, Regional Hospital in Puławy, Poland.
Department of Urology, Collegium Medicum at the Jagiellonian University, Cracow, Poland.
Cent European J Urol. 2015;68(3):340-7. doi: 10.5173/ceju.2015.616. Epub 2015 Sep 26.
Despite improvements in surgical techniques and implementation of minimally invasive procedures, male stress urinary incontinence affects a substantial number of patients after prostatic surgery. In response to increasing demand of optimal treatment modality, new alternatives to artificial urinary sphincter have recently been introduced. This review summarises the therapeutic surgical options with their outcomes in management of postprostatectomy stress incontinence.
We performed a literature review by searching the PubMed, Web of Science and Embase databases for articles published from January 2000 until April 2015 based on clinical relevance.
Artificial urinary sphincter is currently considered the "gold standard" treatment of male stress urinary incontinence. Although the new devices in this group have recently been investigated, the AMS 800 remains the only widely used implant. Male slings and adjustable continence devices, achieve the social continence rates up to 60%. Periurethral injections of bulking agents, have limited efficacy of male stress incontinence. Argus sling and ProACT are both associated with substantial explantation rates. Stem cell therapy is a promising option but still requires additional testing.
The development of new alternatives to artificial urinary sphincter is constantly progressing. Although recently introduced minimally invasive treatment options have not yet surpassed the outcomes of the artificial urinary sphincter they should continue to be evaluated and compared against the gold standard.
尽管手术技术有所改进且微创程序得以实施,但男性压力性尿失禁仍影响着大量前列腺手术后的患者。为了满足对最佳治疗方式日益增长的需求,最近引入了人工尿道括约肌的新替代方案。本综述总结了前列腺切除术后压力性尿失禁管理中的治疗性手术选择及其结果。
我们通过检索PubMed、科学网和Embase数据库,对2000年1月至2015年4月发表的基于临床相关性的文章进行了文献综述。
人工尿道括约肌目前被认为是男性压力性尿失禁的“金标准”治疗方法。尽管最近对该组中的新装置进行了研究,但AMS 800仍然是唯一广泛使用的植入物。男性吊带和可调节控尿装置的社会控尿率可达60%。尿道周围注射填充剂对男性压力性尿失禁的疗效有限。阿格斯吊带和ProACT的取出率都很高。干细胞疗法是一个有前景的选择,但仍需要进一步测试。
人工尿道括约肌新替代方案的开发在不断推进。尽管最近引入的微创治疗方案尚未超过人工尿道括约肌的治疗效果,但仍应继续对其进行评估并与金标准进行比较。